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Abstract
Bovine CD38/NAD
+glycohydrolase (bCD38) catalyses the hydrolysis of NAD
+ into nicotinamide and ADP-ribose and the
formation of cyclic ADP-ribose (cADPR). We solved the crystal structures of the mono N-glycosylated forms of the ecto-
domain of bCD38 or the catalytic residue mutant Glu218Gln in their apo state or bound to aFNAD or rFNAD, two 29-
fluorinated analogs of NAD
+. Both compounds behave as mechanism-based inhibitors, allowing the trapping of a reaction
intermediate covalently linked to Glu218. Compared to the non-covalent (Michaelis) complex, the ligands adopt a more
folded conformation in the covalent complexes. Altogether these crystallographic snapshots along the reaction pathway
reveal the drastic conformational rearrangements undergone by the ligand during catalysis with the repositioning of its
adenine ring from a solvent-exposed position stacked against Trp168 to a more buried position stacked against Trp181. This
adenine flipping between conserved tryptophans is a prerequisite for the proper positioning of the N1 of the adenine ring
to perform the nucleophilic attack on the C19 of the ribofuranoside ring ultimately yielding cADPR. In all structures,
however, the adenine ring adopts the most thermodynamically favorable anti conformation, explaining why cyclization,
which requires a syn conformation, remains a rare alternate event in the reactions catalyzed by bCD38 (cADPR represents
only 1% of the reaction products). In the Michaelis complex, the substrate is bound in a constrained conformation; the
enzyme uses this ground-state destabilization, in addition to a hydrophobic environment and desolvation of the
nicotinamide-ribosyl bond, to destabilize the scissile bond leading to the formation of a ribooxocarbenium ion intermediate.
The Glu218 side chain stabilizes this reaction intermediate and plays another important role during catalysis by polarizing
the 29-OH of the substrate NAD
+. Based on our structural analysis and data on active site mutants, we propose a detailed
analysis of the catalytic mechanism.
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Introduction
Mammalian NAD
+glycohydrolases (NADases; EC 3.3.2.5 and
3.2.2.6) catalyze the hydrolytic cleavage of the nicotinamide-ribose
bond of NAD(P)
+. Most of them also catalyze base-exchange
(transglycosidation) reactions giving access to pyridinium analogs
of NAD(P)
+. For many decades NADases were considered to form
a rather heterogeneous group of enzymes, in terms of apparent
molecular weights and catalytic properties, that are widely
distributed in many organisms [1]. The kinetic and molecular
mechanisms of these enzymes have been extensively studied [1,2]
and, in this respect, bovine spleen NAD
+glycohydrolase represents
an archetypal NADase we have thoroughly investigated over the
years [3].
In sharp contrast with the results derived from studying the
molecular enzymology of NADases, knowledge of their structure
and the deciphering of their biological function(s) remained
limited. Although preponderantly described as ecto-enzymes [4],
some NADases were also found in intracellular compartments of
various tissues/cells and a role in NAD
+ salvage pathways was thus
tentatively ascribed to this class of enzymes. This situation
experienced an unexpected paradigmic shift with the discovery,
in invertebrates, by the group of H.C. Lee, of cyclic ADP-ribose
(cADPR), a new calcium mobilizing messenger [5], and of ADP-
ribosyl cyclase, a soluble enzyme able to convert NAD
+ quasi-
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34918exclusively into this cyclic metabolite [6]. Determination of the
structure of the cyclase from Aplysia californica revealed its striking
structural similarity with human CD38 (hCD38), a 46-kDa type II
transmembrane glycoprotein known as a surface antigen of
lymphoid cells of unknown biochemical functions [7]. It was then
established that mammalian CD38 were indeed enzymes over-
whelmingly endowed with NAD
+glycohydrolase activity. In
addition, CD38 is also able to catalyze the conversion of NAD
+
to cADPR, albeit only with very low yields [8], and the hydrolysis
of cADPR to ADP-ribose (ADPR) [9]. GPI-anchored CD157
represents an additional member of the CD38/ADP-ribosyl
cyclase gene family. Its catalytic functions which, compared to
NADases and CD38 were less explored, are quite similar although
characterized by a much lower efficiency [10]. Simplifying our
perception of these different enzymes, our group has subsequently
shown that the much studied ‘classical’ bovine NADase was also
able to catalyze, like CD38, ADP-ribosyl cyclase (,2% of reaction
products) and cyclic ADP-ribose hydrolase reactions [11,12]. After
partial peptide sequence determination and molecular cloning, the
32-kDa bovine NAD
+glycohydrolase was finally identified as a
member of the CD38 family [13]. Thus, the world of the classical
mammalian NAD
+glycohydrolases merged with that of CD38
[14].
After cADPR, NAADP
+ whose biosynthesis was ascribed to a
base-exchange reaction between NADP
+ and nicotinic acid
catalyzed by CD38, also joined the ranks of potent calcium
mobilizing metabolites [15]. Finally ADP-ribose, the main
reaction product of CD38 was also shown to regulate calcium-
permeable TRPM2 channels [16]. Altogether CD38 appears to be
a key player in the biosynthesis of calcium messengers which are
involved in a wide range of cellular functions [17]. Since the
catalytic activity of CD38 is also related to diseases, such as
diabetes, asthma, and inflammation, this enzyme is an interesting
pharmacological target.
The observed ‘multifunctionality’ of CD38 prompted a
reinvestigation of the mechanism of bovine CD38/NAD
+glycohy-
drolase (bCD38). We have demonstrated the occurrence of an
unifying partitioning mechanism that applies to all members of the
CD38/ADP-ribosyl cyclase enzyme family [12,18], which was
borne out by other groups [19]. Thus, the catalytic transformation
of NAD
+ involves the formation, via a ribooxocarbenium ion-like
transition state (Figure 1), of a unique reaction intermediate that
partitions between several competing pathways such as an
irreversible hydrolytic process leading to ADP-ribose and a
reversible minor pathway that governs the formation of cADPR
[3].
Bovine CD38/NAD
+glycohydrolase presents some distinct
structural features amongst mammalian CD38. Its ecto-domain
shares about 48% sequence identity with the ecto-domain of
hCD38. It is missing seven residues at the C-terminus and an
otherwise highly conserved disulfide bond [13]. Furthermore,
bCD38 contains only two N-glycosylation motifs, of which just one
is occupied at Asn201 [20], instead of the four observed in all
others CD38. The impact of these differences on the structure and
the mechanism of bCD38 is unknown.
In this extensive crystallographic study we report five high
resolution (1.55–1.95 A ˚) structures of the mono N-glycosylated
ecto-domain of wild-type (wt) bCD38 and a catalytic residue
mutant (E218Q) in apo, non-covalent and covalent complexes,
captured with 29-fluorinated analogs of NAD
+ acting as mecha-
nism-based inhibitors. Besides affording the structure of a novel
CD38 distinct from the human one [21], our main aim was to
elucidate mechanistic aspects of this enzyme at a molecular level
such as: i) the destabilization of the nicotinamide-ribose bond in
NAD
+ which has represented a puzzle to enzymologists for many
years, ii) the reaction intermediate stabilization, and iii) the origin
of the low percentage of transformation of NAD
+ into cADPR.
Our structures survey and sample different enzyme-substrate
conformational and reactive states along the catalytic pathways
mediated by CD38. These crystallographic snapshots reveal the
drastic conformational rearrangements undergone by the substrate
within the catalytic site. Our structural investigations of bCD38
provide clear insights into the modalities of substrate binding that
are relevant to the scissile bond destabilization and to the
cyclization process. Based on our structural analysis combined to
enzymatic measurements on active site mutants, we propose a
detailed analysis of the catalytic mechanism for this enzyme.
Results and Discussion
Architecture of bovine CD38
As reported previously, we have expressed in Pichia pastoris a
recombinant form of bovine CD38/NAD
+glycohydrolase trun-
cated for the first 31 amino acids that encompass the transmem-
brane and short intracellular domains [20]. The construct used for
crystallization consists in this soluble ecto-domain (residues 32–
278) of bCD38 [13]. In contrast with the other known mammalian
CD38, such as hCD38 which contains four N-glycosylation sites
[7], bCD38 is a mono-glycosylated protein at position Asn201 and
its only other sequon at Asn268 is unoccupied [20]. The
glycosylation of bCD38 did not prevent crystallization or adversely
affect the diffraction quality of crystals. The 1.8 A ˚ structure of apo
bCD38 was solved by molecular replacement using the known
hCD38 structure (PDB code 1yh3) as model [21]. The invariant
glutamate 218 identified as the catalytic residue of bCD38 (see
below) was mutated into glutamine (E218Q); the structure of this
mutant was solved at high resolution (1.55 A ˚) (Table 1 and
Material and Methods).
The L-shaped structure of bCD38 consists of two distinct
domains separated by a cleft and connected by a hinge region
(Figure 2A). a-Helices are found mainly in the N-terminal and
membrane-proximal domain of this transmembrane protein,
whereas b-sheets are preponderant in the distal C-terminal
domain. The N-ter domain (residues 41–110 and 137–191) is a
bundle of five a-helices (a1, a2, a3, a5 and a6) and the C-ter
domain (residues 113–134 and 194–278) consists of a four-
stranded parallel b-sheets (b1, b2, b3 and b4) surrounded by two
long (a4 and a8) and two shorter and more dynamic a-helices (a7
and a9). Residues 111–112, 135–136, and 192–193 constitute the
hinge region. As predicted [13], bCD38 is stabilized by four
disulfide bonds, Cys59–Cys75, Cys92–Cys172, Cys152–Cys165
and Cys244–Cys265, which are conserved in all members of the
CD38/ADP-ribosyl cyclase family. The bovine C-terminal
domain is naturally shorter by 12 amino acids compared to the
other CD38, and is thus missing their fifth and otherwise
conserved disulfide bond (Cys287–Cys296 in hCD38) with no
consequences on its catalytic activity. However, like hCD38, a
supplementary disulfide bond absent in invertebrate ADP-ribosyl
cyclases and which seems unique to CD38, was also found
between Cys112 and Cys193 of bCD38, stabilizing its hinge
region (Figure 2A). We have shown previously [13], that the N-
terminal a1 helix is dispensable for the conformational stability of
the bovine enzyme and for its catalytic activity (Figure S1). The
overall architecture of the glycosylated form of bCD38/NAD
+-
glycohydrolase shows a great resemblance to its hCD38 homolog,
which has 39% sequence identity and whose four N-glycosylation
sites were silenced by mutagenesis [21]. Superposition of the
E218Q mutant on the wt apo enzyme showed no differences
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nature of the mutation. This suggests that the active site geometry
is maintained in the mutant and that the kinetic effects of the
mutation (see below) are due to an intrinsic catalytic function of
Glu218 side chain.
bCD38 associates as a parallel ‘back-to-back’ homodimer
All crystals of wt bCD38 and mutant belong to the
orthorhombic space group P212121 with two molecules of enzyme
in the asymmetric unit associated as a ‘pseudo’ dimer (Figure 2A)
with a quasi-two fold axis of symmetry; the dimer associates in a
parallel ‘back-to-back’ arrangement with a buried surface area (BSA)
of 3,168 A ˚ 2 for a total accessible surface area (ASA) of 23,000 A ˚ 2.
The dimer interface involves essentially the hinge regions of the
two monomers, the loops between helices a1 and a2 (N-ter
domain) and between helix a8 and strand b4 (C-ter domain), the
helices a3 and part of the helices a6 of both monomers. The
contacts between the monomers consist mainly in polar and
charged residues, i.e. Gln80, Asp235, Asp242, Arg71, Arg73,
Arg79, Arg187, Arg233 and Arg259. Sulfate ions, present in the
crystallization liquor, act as counterions stabilizing this association.
The hCD38 structure also revealed the occurrence of a
homodimer; however, it is arranged in an anti-parallel ‘head-to-
tail’ manner [21,22]. The dimers of the ADP-ribosyl cyclase from
A. californica [23] with BSA and ASA values of 2,511 A ˚ 2 and
22,582 A ˚ 2 or the human CD157/BST-1 [24] with BSA and ASA
values of 5,148 A ˚ 2 and 21,484 A ˚ 2 are both organized in a parallel
‘head-to-head’ manner. It is not clear whether any of these
association states are biologically relevant, moreover no coopera-
tivity between active sites has been found in kinetic studies on
either soluble truncated or detergent-solubilized forms of bovine
CD38/NAD
+glycohydrolase [25,26]. However glycosylations are
likely to hinder a ‘face-to-face’ association, consequently the ‘back-
to-back’ glycosylated (and thus more realistic) bCD38 dimeric
structures described here are more likely to represent the
biologically significant assembly.
These observations are worth discussing within the context of
cADPR cellular biology. The head-to-head dimer arrangement
observed in the A. californica cyclase, was extended by homology to
the cell surface anchored hCD38 [23]. This model was since
extensively used in literature to solve the ‘topological paradox’ of
CD38, suggesting that the ‘cavity’ created by two facing active sites
might shield or sequester the reaction product cADPR and thus
favor the transport of this Ca
2+-mobilizing messenger across the
cell membrane [17]. As mentioned above, this seems now to be
excluded by the crystallographic studies on mammalian CD38.
Moreover, although a homodimeric form of CD38 could be
demonstrated at the surface of murine B cells [27], the divergent
structural data of bovine and human CD38 suggest that such a
topological arrangement cannot be based on extensive and specific
interactions between their ecto-domains. Finally it remains
puzzling that only two transmembrane domains (or four as
suggested in some model systems [28]), might serve as a channel
specific for a molecule as sophisticated as cADPR, when such
known transporters are formed by at least six transmembrane
domains [29]. Thus, as suggested before [28], it is much more
likely that CD38 reaction products are taken up by cells via
nucleoside transporters such as connexin (Cx43) hemichannels
[30] rather than by dimers/oligomers of CD38.
The N-linked glycosylation is near the active site
This is the first structure revealing a N-glycosylated form of
CD38. A single oligomannose-type sugar antenna, GlcNAc2-
Manx, was expected to be present in the structure of recombinant
bCD38. In the crystals, a GlcNAc2 unit covalently N-linked to the
side chain of Asn201 was indeed well defined in the experimental
electron density maps, shown in the 2mFo-DFc map in Figure S2.
This N-glycosylation occurs at a highly conserved residue of the
Figure 1. Partitioning reaction mechanism of bCD38. The nicotinamide-ribosyl bond of NAD
+ is cleaved via a dissociative process with a late
transition state, leading to a ribooxocarbenium ion reaction intermediate stabilized by the side-chain of invariant Glu218. This rate-determining step
is followed by two nucleophilic reactions in competition: (i) an intermolecular pathway involving a rapid trapping from the b-face of this intermediate
by a water molecule (NAD
+ glycohydrolase activity) or by competing neutral nucleophiles such as pyridines (transglycosidation reactions) or alcohols
(e.g., methanolysis), and (ii) an intramolecular reaction between N1 of the adenine ring and C19 (anomeric carbon) of the oxocarbenium ion leading to
the formation of cyclic ADP-ribose (ADP-ribosyl cyclase activity). This latter reaction represents a kinetically minor step (,1% reaction products)
relative to solvolysis.
doi:10.1371/journal.pone.0034918.g001
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the catalytic site. The orientation of the carbohydrate antenna is
fixed by the stacking of its first N-acetyl glucosamine unit (NAG1)
to the protein through direct or water-mediated hydrogen bonds
and hydrophobic interactions surrounding its N-acetyl group
(Figure S3). In contrast, the NAG2 unit does not interact with the
protein. The possibility that the rest of the antenna, which is
invisible, might be able to shield the outer surface of the enzyme
near the solvent-exposed entry of the active site pocket remains an
open question.
The active site
Residues Trp118, Glu138, Asp147, Trp181 and Glu218 were
predicted by homology with hCD38 [31–33] to be involved in the
molecular mechanism of bCD38. They actually outline its
catalytic site, and are all clustered in a pocket located at the
junction of the N- and C-ter domains of the protein. The active
site of bCD38 consists in the largest solvent accessible cavity
detected at the surface of the protein. This 12 A ˚ deep funnel-
shaped cavity is also 12 A ˚ wide at its entrance. The total volume of
this highly hydrated cavity is about 350 A ˚ 3 (Figure 2B). A cluster of
three strictly conserved phenylalanine residues (Phe117, Phe188
and Phe214) acts as a hydrophobic ‘plug’, sealing the bottom of
this pocket. A similar arrangement of Phe residues was recently
described in the active site of the sirtuin Sir2Tm [34]. Importantly,
the bottom of the active site in bCD38 has distinct structural
characteristics: in reason of the tight packing of the protein in this
region (residues 116–118, 136–138, 185 and 188) it consists in a
very rigid and geometrically constrained system. Moreover the
relative accessible surface of the residues at bottom the pocket is
very low. For example, one can estimate (NACCESS program)
that only 8% of the surface of Glu218 side chain is solvent
Table 1. X-ray diffraction data and structure refinement statistics for wild-type bCD38 and E218Q mutant structures.
Structure wt bCD38
wt bCD38 covalent
complex with aFNAD
wt bCD38 covalent
complex with
rFNAD mutant bCD38
mutant bCD38 NON-
covalent complex with
rFNAD
PDB ID 3GH3 3P5S 3KOU 3GC6 3GHH
Data set statistics ALS100606 ALS250407 ALS060507 ALS250407 ALS060507
Wavelength (A ˚) 1.11587 1.11587 1.11587 1.11587 1.11587
Space group P212121 P212121 P212121 P212121 P212121
Cell dimensions
a (A ˚) 47.4 46.2 46.7 47.0 46.4
b (A ˚) 80.9 80.0 81.3 80.2 79.4
c (A ˚) 151.8 157.7 150.9 152.5 156.3
Resolution (A ˚) 50.0–1.80 80.2–1.95 75.4–1.78 80.1–1.55 50.0–1.94
(last shell) (A ˚) (1.86–1.80) (2.06–1.95) (1.88–1.78) (1.61–1.55) (2.01–1.94)
Unique reflections 53,100 (4,812) 39,086 (5,881) 52,041 (6,599) 74,734 (4,271) 41,975 (4,109)
Redundancy 3.9 (3.4) 2.9 (2.7) 3.5 (3.3) 3.3 (1.3) 3.4 (3.1)
Completeness (%) 97 (89) 90 (94) 93 (82) 82 (33) 96 (96)
I/s(I) 26.0 (2.9) 7.1 (2.1) 8.0 (1.5) 16.9 (1.5) 11.2 (2.0)
Rsym (%) 3.4 (30.6) 8.4 (39.1) 9.9 (77.5) 3.5 (31.8) 7.2 (61.0)
Refinement statistics
Resolution range (A ˚) 40.4–1.80 78.8–1.95 75.4–1.78 76.2–1.55 78.1–1.94
Reflections used work (test) 47,191 (3,873) 34,641 (2,902) 47,602 (4,018) 63,095 (5,756) 38,617 (3,242)
Rfree (%)/Rfac (%) 22.3/17.7 25.6/20.5 24.3/20.0 21.0/18.7 25.4/20.6
Overall figure of merit 0.932 0.890 0.920 0.950 0.917
Overall Bwilson (A ˚2) 1 82 6 2 22 12 8
Protein atoms, B (A ˚2) 3,892, 29 3,811, 33 3,798, 28 4,022, 39 3,855, 38
Ligand atoms (A ˚2) no ligand 70, 37 52, 29 no ligand 41, 47
Solvent atoms, B (A ˚2) 528, 39 355, 36 368, 33 488, 49 280, 42
Carbohydrate atoms, B (A ˚2) 56, 62 28, 58 42, 42 56, 65 56, 59
Ions, B (A ˚2) 2 sulfates, 90 2 sulfates, 48 2 sulfates, 58 5 sulfates, 65 4 sulfates, 61
1 cacodylate, 78
rmsd bonds (A ˚)
a 0.008 0.007 0.011 0.011 0.006
rmsd angles (u) 1.124 1.226 1.204 1.265 1.098
Ramachandran analysis
Preferred regions (%) 95.9 95.8 92.9 95.9 92.0
Allowed regions (%) 3.9 3.8 6.0 3.9 5.4
Outliers (%) 0.2 0.4 1.1 0.2 2.6
doi:10.1371/journal.pone.0034918.t001
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by the conserved residue Trp181 also constitutes a rigid part of the
active site.
The invariant Glu218 which was identified as the catalytic
residue of bCD38 by site-directed mutagenesis followed by kinetic
analysis of the mutants (Table 2 and I. Kuhn et al., to be
published) and by use of mechanism-based inhibitors (see below),
is located at the very bottom of the active site pocket. This residue
is separated from the highly conserved residue Glu138 (which is
part of the TLEDTL ‘signature motif’ of the CD38/ADP-ribosyl
cyclase enzyme family) by 7.8 A ˚. This distance can be compared
to that of ,5.5 A ˚ which typically separates the catalytic
nucleophile and acid/base pairs of carboxylic acids in the
retaining b-glycosidases [35]. The subsite in the vicinity of
Glu218 is surrounded by side chains of hydrophobic residues
including the Phe ‘plug’ and residues Trp118, Leu137, Ala189,
Ile213, Ala219 and Val 217 which are all within a 6 A ˚ radius
around its Ce atom. Ser185, whose hydroxyl group is already
involved in a hydrogen bond with Trp181 backbone (d=2.7 A ˚), is
the only other polar residue present in this pocket. It is in
proximity with Glu218 at a distance (Oe2
…O=3.7–3.8 A ˚)
allowing a low energy hydrogen bond. Interestingly, nonbonded
anion-p pairs have recently been suggested to occur in the
stabilization of protein structures and in protein-ligand interac-
tions [36]. The edgewise interactions observed between the cluster
of buried phenylalanines and the Glu218 side chain (Figure 2B)
fulfill the criteria of a stabilizing energy for this carboxylate group.
In the unliganded state, Glu218 is also stabilized by water
molecules, e.g. two molecules bridge via hydrogen bonds its Oe1
and Oe2 atoms with the backbone amide group of Trp118.
Similarly, in the E218Q mutant, both Oe1 and Ne2 atoms of the
amide group of Gln218 are interacting with water molecules and
the Ne2 is at a distance of 2.9–3.0 A ˚ from the oxygen atom of
Ser185 side chain. Several other water molecules are present in
this region of the active site of apo wt bCD38; four of them are in
line and hydrogen bonded to the backbone of the first b-strand of
bCD38 C-ter domain between residues Val116 and Lys120. This
cluster of water molecules could provide a means of access for bulk
water to the bottom of the active site. Among these residues,
Trp118 and Lys120 are important in catalysis and binding (see
below).
In apo bCD38, the residues of the ‘signature motif’, despite
being solvent-exposed, have also a limited conformational
flexibility. This is mainly due to the occurrence of an extensive
hydrogen bond system that also involves water molecules (Figure
S4B). Thus, Glu138 is taking part to a hydrogen-bond network
formed with two other highly conserved residues. The Oe1 atom
of its side chain is hydrogen bonded (2.9 A ˚) to N1 of the indole
ring of Trp118 and to the Ne2 position (2.9 A ˚) of His126 side
chain. The other atoms, i.e. Oe2 of Glu138 and Ne1 of His126,
are all engaged in hydrogen bonds with water molecules. The
carboxylate of Asp147 is within a distance of Lys122 e-amino
group to give an ion-pair (,3.3 A ˚) and is also surrounded by water
molecules.
The use of 29-fluorinated analogs of NAD
+ to trap non-
covalent and covalent complexes of bCD38
Soaking crystals of the catalytically impaired E218Q mutant of
bCD38 with NAD
+ failed to capture uncleaved substrate or any of
the reaction products, nicotinamide and ADP-ribose. This
indicates that the residual activity of bCD38, in which the
catalytic Glu218 was mutated to Gln, is still too high (relative
kcat,1/2000; Table 2) to allow the trapping of the Michaelis
complex with the physiological substrate and, importantly, that the
active site residues remained catalytically competent in the crystal
of the mutant. Next we replaced NAD
+ with 29-deoxy-29-b-D-
fluororibofuranoside NAD
+ (rFNAD), a close (bioisosteric) struc-
tural analog carrying a fluorine atom at position 29 of the ribose
moiety linked to nicotinamide (N-ribose) (Figure 3A). As described
previously, substitution of the 29-OH group of N-ribose by a
strongly electronegative atom adjacent to the reaction center does
not affect the affinity of the analog for the active site of bCD38,
but inductively destabilizes the oxocarbenium ion transition state
(Figure 1) and impacts the catalytic rate which is considerably
reduced (i.e. 4.8610
5-fold relative to NAD
+) [37]. Using this
strategy, we were able to trap a non-covalent complex between the
E218Q mutant and rFNAD and its structure was solved at 1.94 A ˚
(Table 1). However, for unknown reasons, we were unable to
obtain the corresponding Michaelis complex between the mutant
and 29-deoxy-29-b-D-fluoroarabinofuranoside NAD
+ (aFNAD). In
parallel, we also attempted to trap Michaelis complexes by soaking
Figure 2. Overview of the structure of bCD38 and its active site.
(A) Structure of the homodimer of the ecto-domain (D31) of wt apo
bCD38 observed in the asymmetric unit; the non-crystallographic two-
fold axis is indicated. (B) The active site of bCD38. The side chains of
selected residues participating to the catalytic activity of the enzyme
are indicated in grey. The phenylalanine ‘plug’ is in orange. Catalytic
residue Glu218 sits at the bottom of the active site pocket. Secondary
structure elements are labeled. The N- and C- terminal domains are
indicated. The five disulfide bonds stabilizing each monomer are
depicted in green and a red asterisk indicates the disulfide bond
specific to CD38 that stabilizes its hinge region. The sugar chains bound
to residues Asn201 are shown in stick representation. The active sites
are indicated with arrows.
doi:10.1371/journal.pone.0034918.g002
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However both 29-fluorinated analogs of NAD
+ led to high-
resolution structures (Table 1) which lacked the nicotinamide ring
and where a covalent bond was observed between the carboxylate
of Glu218 and C19 of the 29-fluorinated N-ribose moieties of the
analogs (Figure 3B). The structures of the non-covalent and
covalent complexes of bCD38 with rFNAD and aFNAD are
described below and the electron density maps of each of the
described ligands are shown in Figure S5. They provide invaluable
insights into the catalytic mechanism of this enzyme that are also
addressed.
At this point it is important to discuss the activity retained by the
E218Q mutant of bCD38 (Table 2). It contrasts sharply with the
absence of measurable activity exhibited by the homologous
E226Q mutant of human CD38 [31] giving access, for this
enzyme, to the Michaelis complex with NAD
+ [38]. We have
recently confirmed these data [39] and found that the activity of
the E226Q mutant was at least 10
6-fold inferior to that measured
for wt hCD38. However, this residual activity of the E218Q
mutant of bCD38 represents a true catalytic activity and not the
result of contamination by wild-type enzyme (Materials and
Methods) or from the expression system, i.e. no CD38/
NAD
+glycohydrolase-like activity was detectable in supernatants
of Pichia pastoris cultures. Furthermore it is highly reproducible and
a similar range of activity was found with the E218A mutant (I.
Kuhn et al., to be published). Finally, in sharp contrast with wt
bCD38, the E218 mutants are non-competitively inhibited by
pyridine bases (I. Kuhn et al., to be published) ruling out their
identity with the wt enzyme. Altogether our results indicate that
the E218Q mutant still carries a measurable residual catalytic
activity. Moreover the discrepancy between bovine and human
enzymes suggests that the reactions catalyzed by these two
enzymes might display a different sensitivity towards the mode
of action of their catalytic Glu, thus validating the study of bovine
CD38.
Structure of the non-covalent complex of E218Q mutant
with rFNAD: the Michaelis complex
Despite the presence of two CD38 molecules in the asymmetric
unit of E218Q mutant of bCD38, the structure of the non-covalent
complex with rFNAD revealed that only one site is fully occupied;
it is possible that one of the monomer and active site are rendered
less accessible and/or reactive due to crystalline packing
constraints.
Highlighting its conformational rigidity, the active site of
bCD38 does not undergo important structural modifications upon
rFNAD binding. The backbone position is well conserved;
typically, the RMSD computed for the position of Gln218,
Glu138, Trp118 and Trp181 backbone atoms is about 0.2 A ˚ when
comparing the apo E218Q mutant and the Michaelis complex.
Table 2. Site-directed mutagenesis analysis of the role of selected active site residues on the steady-state kinetic parameters of
NAD
+ transformation catalyzed by bCD38.
Enzyme Km (mM) kcat (s
21) relative kcat cyclization (%)
a kcat/Km (mM
216s
21) relative kcat/Km
wild-type 17.160.3 57.961.9 1 1.160.3
b 3.3860.13 1
K120A 27.763.4 47.162.1 0.81 ,2 1.7060.22 0.50
W168A 24.664.2 19.660.9 0.34 ,20 . 8 60.14 0.24
S185A 18.762.8 38.261.3 0.66 ,2 2.0460.31 0.60
R216A 22.963.4 25.461.1 0.43 ,21 . 1 60.17 0.32
E218Q 24.765.7 (3.060.2)610
22 0.00052 1.160.1
b (1.2160.3)610
23 0.00036
aConversion of NAD
+ into cADPR, in percent of the reaction products,
bcADPR was determined using the cycling assay, the other data were obtained using a radiometric HPLC assay with
14C-NAD
+ as substrate.
doi:10.1371/journal.pone.0034918.t002
Figure 3. Chemical structure of rFNAD and aFNAD and their
corresponding covalent intermediates with Glu218. The 29-
fluorinated analogs of NAD
+ (A) are slow substrates of bCD38 that can
covalently react with the catalytic residue Glu218 (B). The asterisk
designates C19 of the furanoside ring that forms the covalent bond with
the carboxylate group of Glu218. The standard numbering is indicated.
(C) Overview of the structure of the Michaelis complex with rFNAD. The
ligand is shown non-covalently bound in the active site of the bCD38
E218Q mutant.
doi:10.1371/journal.pone.0034918.g003
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positioning. Thus, the most significant one in the buried part of
the active site concerns Ile213; two different rotamers are observed
in the apo enzyme, none being suitable for the placement of the
nicotinamide moiety of rFNAD. A third rotamer was indeed
selected in the Michaelis complex. The conformation of the
Gln218 amide group was also constrained by the bound rFNAD
ligand, with adjustments in the torsion angles around Cb-Cc (x2)
and Cc-Cd (x3).
rFNAD is a bulky ligand (volume ,176 A ˚ 3) and its electron
density in the non-covalent complex with the E218Q mutant is
well defined thus revealing its conformation (Figure 3C). In
particular the ribose from the adenosine part is well-resolved in
density. This NAD
+ analog is constrained by the enzyme in a
somewhat folded conformation and is stabilized in the active site
by extensive interactions (Figure 4A). The distance between C6A
and C2N, usually used to define the proximity between the
adenine and nicotinamide rings and the folding of NAD(P)
+ within
the active site of enzymes [40], is 9.3 A ˚ in the present Michaelis
complex. It thus appears that bCD38 binds rFNAD in a
conformation much less extended than the majority of NAD(P)
+
binding enzymes with Rossmann folds, and other NAD
+ cleaving
enzymes such as diphtheria toxin, sirtuins or ART2.2 where this
distance is .12 A ˚ [40].
The active site of bCD38 can be divided into adenosine,
pyrophosphate and nicotinamide-ribosyl binding sites. The
electron density maps show that the nicotinamide ring of rFNAD
is buried in the active site in agreement with the experimental
observation that the cleavage of the nicotinamide-ribosyl bond is
the first step of catalysis. In the Michaelis complex the leaving
group fills a hydrophobic bulge in the upper half of the active site
near the signature motif and is positioned through concerted
interactions involving strictly conserved residues (Figure 4A).
Thus, the N7 atom of its carboxamide group is hydrogen bonded
to Oe1 of the carboxylate group of Glu138 (d=2.7 A ˚) and Asp147
(at a suboptimal distance=3.3 A ˚). This binding pulls the
nicotinamide moiety to the bottom of the active site, thus
triggering an extensive desolvation of this subsite and the
disruption of the hydrogen bond network observed in the
unliganded enzyme structures. However, a water molecule
remains bridging the O7 of the nicotinamide moiety (d=2.6 A ˚)
and the amide backbone group of Gly148. Within the complex
and in contrast with the apo structure, Glu138 is no longer
hydrated. Interestingly this residue remains however hydrogen
bonded to the indole ring of the conserved residue Trp118
(Oe1
…N1 d=2.84 A ˚); this underlines the rigidity of the active site
whose local topology is unaltered by the binding of the
nicotinamide-ribosyl moiety of the ligand. The indole ring of
Trp118 now stacks with C29-H and C39-H on the hydrophobic
top-face of the 29-deoxy-29-fluororibose ring. Such CH
…p
interactions have been frequently described between tryptophan
side chains and donor CH groups polarized by neighboring
heteroatoms or halogens [41]. As mentioned above, the Oe2 atom
of the carboxylate of Glu138 could be hydrogen-bonded to His126
which thus may serve as a proton relay between the catalytic
center and the bulk solvent. As in wt bCD38, the Od1 from
Asp147 is also bonded to the side chain of Lys122. From a
mechanistic perspective, positioning of the nicotinamide moiety by
Glu138 and Asp147 in the vicinity of Trp118/Trp181 probably
shields the anomeric center of the N-ribose from bulk solvent until
breakage of the scissile bond and the exit of nicotinamide out of
the active site. Moreover, Trp118 adopts an ideal position to
participate to catalysis through cation-p interactions with the
oxocarbenium ion that develops in the transition state and in the
stabilization of an oxocarbenium ion-like reaction intermediate.
The indole ring of Trp181 is found in proximity of the
nicotinamide moiety of bound rFNAD (Figure 4A). This conserved
residue was suggested to be involved in hCD38 in the positioning
of the nicotinamide moiety of the substrate via p-p interactions
[33,38]. Because of the positively charged pyridinium ring, a more
energetic cation-p interaction [42,43] between the nicotinamide
and the indole group should rather be considered. However, from
a catalytic perspective such an interaction leading to the
stabilization of the ground state (Michaelis complex) would be
rather counterproductive. Indeed, stabilization for pyridinium
derivatives – resulting in an increase of the leaving group pKa –
through cation-p interactions with tryptophan side chain in the
ground-state has been well documented [44]. In the rFNAD/
E218Q complex, the distance between the pyridinium charge and
the centroid of the Trp181 indole ring is equal to 5.25 A ˚; thus an
aromatic cation-p interaction (p
+-p interaction) between the
substrate cationic nicotinamide and this active site residue does
not meet the energetically favored parallel-displaced or T-shaped
stacking configurations observed between pyridinium derivatives
and aromatic rings [43] and is considered unlikely or at best
suboptimal. However the topology of the complex illustrated in
Figure 4A presents some mechanistic advantages since when the
scissile bond becomes elongated in the transition state a parallel-
displaced p-p interaction [45,46] can be expected between the
more neutral leaving nicotinamide and the indole ring of Trp181.
Thus we suggest that Trp181 instead of stabilizing the substrate in
its ground state, which would result in an anticatalytic effect,
rather contributes to catalysis by interacting with the leaving group
in the transition state. This hypothesis is fully supported by our
kinetic studies of mutants affecting Trp181 and Asp147 which
show that mutations of these residues affect only kcat values but not
Km (I. Kuhn et al., to be published) which, in bCD38, can be
assimilated to the Michaelis complex dissociation constant [25].
Modeling studies indicate that an elongation of the scissile bond by
,1.0 A ˚ (residual bond order ,0.036) increases the interaction
between the nicotinamide ring and the pyrrole moiety of the side
chain (Supporting Information S1). This movement, which pushes
nicotinamide slightly out of the active site, is also accompanied by
an optimization of its hydrogen bond with Asp147. A further
motion remains necessary to optimize the stacking of nicotinamide
onto Trp181 which, by weakening the hydrogen bonds with
Glu138 and Asp147, might be instrumental in its departure from
the active site.
In the apo structure, the catalytic Glu218 forms no salt bridge
and, besides the distant Ser185 that it might engage in low energy
hydrogen bond, its side chain is only stabilized by water molecules
(see above). Upon formation of the Michaelis complex, this
hydration network is disrupted and displaced by the binding of the
N-ribose moiety of the ligand. As shown in Figure 4A in the
rFNAD/E218Q complex the 29-deoxy-29-fluororibose linked to
nicotinamide is fixed in the active site through efficient hydrogen
bonds between its 39-OH group, which displaces a bound water
molecule, and the Oe1 atom of the mutant residue Gln218
(d=2.7 A ˚) and backbone NH group of Trp118 (d=2.9 A ˚).
The hydrogen-bonding pattern of the fluorine atom in the
catalytic site was also investigated. It is commonly accepted that
electronegative fluorine is a stronger acceptor than the other
halogens but is not as strong as oxygen or nitrogen [47] and C–F
bonds are generally poorly solvated. In the complex with rFNAD,
the 29-ribofluoro substituent however interacts with a structural
water molecule (d(29F
…Wat26)=2.8 A ˚) held in position by the
carbonyl and amide backbone groups from residues Val116 and
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+. (A) Stereo view
showing rFNAD non-covalently bound in the active site of the E218Q bCD38 mutant. Residues critical to substrate binding and catalysis are labeled.
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…H–O bond, where the
fluorine atom is seemingly acting as a hydrogen bond acceptor, is
also observed in the covalent complex with rFNAD (see below).
Although the existence of such hydrogen bonds in protein/ligand
complexes has been controversial [48], their occurrence was
recently described with fluorine substituted glycosides where C–
F
…H2O interactions were observed on binding to lectins or
enzymes [49]. Interestingly, a structural water molecule, with a
similar localization in the narrow end of the active site, was also
found in hCD38 [38].
The interactions of rFNAD established in the present Michaelis
complex can be extrapolated to the binding of NAD
+ to wt
bCD38. As found with similar enzymes such as human CD157
and CD38 [24,50], the 29- and 39-OH groups of the N-ribose of
NAD
+, are expected to make a bidentate interaction with the
carboxylate of the catalytic Glu. Moreover, the displacement by
these two hydroxyl groups of the ordered water molecules
surrounding residue Glu218, might contribute, in a hydrophobic
microenvironment, to the binding energy of the substrate by an
entropic effect (binding entropy). Comparison of bCD38 E218Q/
rFNAD Michaelis complex with that of NMN
+ bound to the active
site of wt hCD38 (PDB code 3dzk; [50]) provided interesting
information. Thus, besides some changes in the x2 and x3 torsion
angles of Gln218 side chain, which generate a strong hydrogen
bond between its Oe atom with the 39-OH group of the ligand, the
absence of a Glu218 and concomitantly the loss of a hydrogen
bond with an 29-OH group, did not significantly affect the
positioning of the nicotinamide-ribosyl moiety of the ligand within
the active site (Figure S7).
The pyrophosphate backbone of rFNAD, which in general
provides great conformational flexibility to NAD
+, interacts
strongly with the protein (Figure 4A). Electrostatic and polar
interactions at the entry of the catalytic site involve a basic residue
Lys120 (Arg127 in hCD38) and the side chains of the two serine
residues Ser119 and Ser212. Of note Lys120 is also a residue
which is in contact with NAG1 of the sugar antenna; however the
shortest distance between this proximal sugar and the pyrophos-
phate bond of the ligand is ,7.7 A ˚ which is too large for an
antenna to affect the access to the active site and ligand binding.
Additional interactions with the bCD38 backbone (NH of Ile213
and Phe214) promote anchoring of the substrate in the catalytic
cleft. In contrast to 29-deoxy-29-fluororibose, the ribose of the
adenosine moiety (A-ribose), shows little interactions, if any, with
the enzyme and is solvent exposed. This observation is in good
agreement with the low discrimination shown by this enzyme
between NAD
+ and NADP
+ which carries an extra 29-phosphate
group [51]. In one of the two monomers of the asymmetric unit
the adenosine moiety appears to be fairly dynamic as demon-
strated by the less well-defined electron density and higher thermal
factors. The adenine ring is recognized through p-p interactions
with the indole ring of the conserved Trp168, a rather flexible
residue situated at the outward edge of the active site pocket, and
by the guanidinium group of Arg216 interacting with its N7
position. These interactions position the adenine ring in a
conformation in which its N1N position is far from the C19of N-
ribose and is thus unsuitable for an efficient ADP-ribosyl cyclase
reaction.
The Michaelis complex and its mechanistic implications
Upon binding the substrate adopts a conformation that buries
the nicotinamide-ribose moiety deep into the bottom of the active
site and triggers the desolvation of the ribose ring and places its
scissile bond within a highly hydrophobic subpocket (C19 is in the
immediate vicinity of Leu137 side chain). The remaining portion
of the substrate is positioned towards the entry of the active site
cavity which is more accessible to the bulk solvent. In the absence
of electrostatic interactions stabilizing the positive charge of the
pyridinium ring of the bound substrate, the microenvironment in
the immediate vicinity of the scissile bond is characterized by a low
dielectric constant. This has several consequences from a
mechanistic standpoint. First, as discussed extensively by Buckley
et al. [52], the desolvation energy provides a significant driving
force for the catalyzed reaction by destabilizing the positively
charged nicotinamide ring in the reactant and thus promoting the
dissociative cleavage of the nicotinamide-ribosyl bond. Second, as
this scissile bond lengthens, the positive charge is gradually
transferred from the nicotinamide ring to the N-ribose C19-O49
bond generating an oxocarbenium transition state stabilized by
electrostatic and cation-p interactions with conserved residues
Glu218 and Trp118 and a p-p interaction between the leaving
nicotinamide and the indole ring of Trp181. As a result, this
ground-state destabilization contributes to catalysis by lowering
the energy difference between the reactant and the late transition
state characterized by a highly delocalized positive charge and an
almost neutral nicotinamide, i.e. in which the nicotinamide-ribosyl
bond is almost broken [53]. Finally, the stabilization of the
oxocarbenium ion intermediate by Glu218 can occur either by
charge-charge stabilization or via a collapse to form a covalent
acylal bond at its C19-position [3]. Importantly, such non-polar
microenvironment-related effects could explain the residual
catalytic activity of Glu218 mutants of bCD38 such as E218Q
(see above). These issues will be fully addressed elsewhere.
In the Michaelis complex Ser185, the only polar residue present
in the apo wt bCD38 in the vicinity of catalytic Glu218, remains
hydrogen bonded to the backbone oxygen of Trp181 (d=2.56 A ˚).
When compared to the apo E218Q mutant, its side chain is now at
a larger distance from Ne2 of Gln218 (d=3.8–4.0 A ˚) and is also
pointing towards the anomeric carbon of the ligand N-ribose
(Figure S8). At a distance of 3.4 A ˚ from C19, the nucleophilic
hydroxyl group of Ser185 is somewhat short of a bonding distance
which might have been deleterious for catalysis, e.g. resulting in a
covalent trapping of the oxocarbenium ion reaction intermediate.
But, as suggested before for hCD38 [38], Ser185 might take part
to the stabilization of this positively charged transition state/
intermediate. However, related to this hypothesis, Ser185Ala
mutation of bCD38 did not result in marked changes of its kinetic
parameters (Table 2), indicating that the part taken, if any, by the
side chain of Ser185 in the stabilization of the transition state of
the reaction catalyzed by this enzyme is minimal. This observation
contrasts with the results found with hCD38 where mutation of the
Hydrogen bonds are indicated with dashed lines. (B) Stereo view showing the rFNAD substrate covalently bound to residue Glu218 in the active site
of the wt bCD38. Residues critical to substrate binding and catalysis are labeled. The water molecule hydrogen bonded to the N7 of the adenine ring
and to the side chain of Glu138 is displayed as a red sphere. Hydrogen bonds are indicated with dashed lines. These two views highlight the
conformational change undergone by the ligand from the ‘extended’ (A) to the ‘folded’ (B) conformation. The flipping of conserved residue Trp168
accompanies this ligand folding within the active site. (C) Superimposition of the rFNAD ligands observed in the Michaelis (yellow) and covalent
(pink) complexes as shown in (A) and (B) respectively. This figure highlights the movement undergone by the adenosine moiety when progressing
from the Michaelis complex to the covalent intermediate. The three views are in the same relative orientation.
doi:10.1371/journal.pone.0034918.g004
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activities of the mutants [38]. In that enzyme, however, Ser193
was mutated to residues carrying bulkier side chains than the
methyl group of Ala; consequently, because they are positioned at
a very short distance from the reaction center C19, they might
have disturbed by steric hindrance the precise molecular
arrangement of the catalytic groups involved in the cleavage of
the scissile bond and thus affected the efficiency of the hCD38
mutants.
The NMN
+ moiety of rFNAD adopts a folded and strained
conformation in the Michaelis complex - Relevance for
catalysis
The interactions of the active site residues of bCD38 with
rFNAD in the Michaelis complex constrain this slow-substrate in
an unusual conformation with regard to its torsion angles. The
bound ligand is illustrated in Figure 5A and the values of selected
torsion angles that are relevant for the molecular mechanism of
bCD38 are given in Table 3. For the nomenclature of the
conformers, see IUPAC-IUB recommendations [54].
Torsion angles of the nicotinamide 3-carboxamide group
and the nicotinamide-ribosyl bond. The hydrogen bond
network involving the invariant active site residues Glu138 and
Asp147 and the nitrogen of the 3-carboxamide group (Figure 4A)
fixes the nicotinamide moiety of the ligand in a conformation
where the exocyclic oxygen atom O7 is trans relative to the C2
position of the aromatic ring, i.e. torsion angle k=2176u
(Table 3). Moreover, the amide, which makes a low out-of-the
plane angle (C4-C3-C7-O7) of ,4.9u, is approximately coplanar
with the pyridine ring. Of note, such a trans conformation is
prevalent in crystal structures reported for enzyme-bound
NAD(P)
+ cofactors [40]. Related to this finding, ab initio
calculations have previously indicated that the carboxamide
group in free N-substituted nicotinamides (such as in NAD
+)
prefers a cis orientation whereas in neutral nicotinamide it prefers
to be trans [55,56]. This indicates that with respect to the amide
group, rFNAD is bound in the Michaelis complex in a high-energy
trans geometry stabilized by specific interactions. In contrast, the
leaving nicotinamide is already in its minimum energy orientation.
Consequently, since the cleavage of the scissile bond catalyzed by
bCD38 occurs via a very late transition state, i.e. product-like [57],
a rate advantage can be expected (Hammond postulate) and
estimated to a lowering of the reaction energy by ,2 kcal.mol
21
[56].
The value of the torsion angle about the N-ribosyl bond of
rFNAD, xN,145u, is very unusual compared to the preferred syn
(60u)o ranti (2120u) conformations measured in NAD
+ bound to
enzymes as coenzyme [40] or as substrate such as in ADP-ribosyl
transferases [58]. This torsion angle is however close to that of
NAD
+ complexed to sirtuins [58]. Such an out of range
conformation, which is also dictated by the hydrogen bonds
between active site Glu138 and Asp147 and the N7 of the
carboxamide group, positions the nicotinamide ring group in an
orientation relative to the ribose ring in which steric interactions
are expected between the hydrogen atom at C6N-position and the
ribose oxygen O49 (d (C6N-O49)=2.74 A ˚). Such steric overlaps,
which are maximum at xN=180u, are known to cause a
lengthening of the scissile bond in the ground- state [40,59]
(C19-N1N=1.51 A ˚). Altogether the steric strain in the Michaelis
complex caused by the value of xN can contribute to make
nicotinamide a better leaving group, and the ground-state
destabilization lower the energy barrier of the reaction.
The occurrence of interactions between the nicotinamide
carboxamide moiety with active site acid residues is in excellent
agreement with our previous kinetic studies on bovine CD38/
NAD
+glycohydrolase-catalyzed hydrolysis of pyridinium analogs
of NAD
+. We have thus shown that a carboxamide group at
position 3 of the pyridine ring provides a hydrolysis efficiency
,14-fold higher (dDG
{=21.65 kcal.mol
21 at 37uC) than expect-
ed from the pKa of the leaving nicotinamide [53]. Consequently,
one could envisage that the combined action of Glu138 and
Asp147 residues (Figure 4A) specifically stabilizes a trans
conformation of the 3-carboxamide substituent and a torsion
angle of the nicotinamide-ribosyl bond that increases the reactivity
of the scissile bond.
Torsion angle about the exocyclic C49–C59 bond. Binding
of rFNAD to the active site of the enzyme enforces a conformation
in which cN, the torsion angle about the C49–C59 bond, is ,161u
(Table 3). Rotation about this exocyclic bond plays a crucial role in
positioning the 59-substituent relative to the ribose and
nicotinamide rings; interestingly, the +ap conformation found for
cN places the exocyclic O59 within a short contact distance of
2.9 A ˚ above the ribose ring oxygen O49 (oxygen stack) (Figure 5C).
Such a conformation is electrostatically unfavorable in the ground
state. Electron donation by a lone pair from the O59 was suggested
to favor the release of electrons from O49, that accompanies the
cleavage of the C19-N1N bond and the formation of the positively
charged oxocarbenium ion [60,61]. Consequently the proximity
between the O59 and O49 atoms is expected to enhance the lability
of the nicotinamide-ribosyl bond through stabilization of the
transition state at the scissile bond cleavage step (see also [62]).
In conclusion, the substrate destabilization occurring in the
Michaelis complex, involving steric and electronic constraints
(ground-state destabilization), which is relieved en route to the
transition state might be part of the arsenal used by bCD38 to
cleave the nicotinamide-ribosyl bond.
Conformation of the AMP moiety of rFNAD adopted in
the Michaelis complex
Despite the observed flexibility of this region of the ligand, the
adenine ring is observed in an anti conformation (xA=2106u)
(Table 3) which corresponds to a conformation strongly preferred
by unbound and protein-bound (di)nucleotides [40,59]. The
pucker of the A-ribose (P=148u) is borderline to the classical
C29-endo conformation. Likewise, the torsion angle measured
about the exocyclic C49–C59 bond, cA=54u, corresponds to a
staggered +sc conformation (Figure 5D) which is predominantly
encountered in nucleosides/nucleotides [59]; this contrasts with
the 2sc conformation which seems to be overwhelmingly favored
for NAD(P)
+ bound to the active site of different enzyme families
[40]. bA the torsion angle, which defines the rotation about the
C59–O59 bond, indicated an 2ap conformation (Figure 5F) which
is somewhat less favored than the +ap one for enzyme-bound
NAD
+ [40,59].
Taken together the interactions of the active site residues with
the nicotinamide 29-deoxy-29-fluororibose moiety of rFNAD
constrain this ligand, in the Michaelis complex, in unusual
conformations with regard to the N-ribose torsion angles with
the leaving pyridine and the C49–C59 bond. It seems very likely
that the distortions and strain introduced by the binding energy
are harnessed by the enzyme to destabilize the scissile bond
already in the ground-state and thus contribute to the catalytic
mechanism. The AMP moiety displays a much more classical
conformation, in line with the rather loose interactions between
the active site and this part of the substrate. As such, the adenine
ring is in an unfavorable anti conformation too far from the
reaction center to engage in a cyclization reaction leading to the
formation of cADPR.
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PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e34918Figure 5. Conformations adopted by rFNAD in the Michaelis and covalent complexes. The conformations of rFNAD as seen in the
Michaelis complex trapped in the E218Q mutant (A) and in the corresponding covalent intermediate generated by the wt bCD38 (B). The two views
are in the same relative orientation. The different torsion angles are indicated on the structures. Newman projections (C–G) showing conformations of
rFNAD in complexes with the active site of bCD38. (C) Rotation around the C49–C59 bond of the NMN
+ moiety of rFNAD in the Michaelis complex
(related torsion angle: cN). Comparison of the rotation around the C49–C59 bond of the AMP moiety of rFNAD (related torsion angle: cA) in the
Michaelis complex (D) and in the covalent complex obtained by reaction with wt bCD38 (E). Comparison of the rotation around the C59–O59 bond
(related torsion angle: bA) of the AMP moiety of rFNAD in the Michaelis complex (F) and in the covalent complex with wt bCD38 (G).
doi:10.1371/journal.pone.0034918.g005
Table 3. Conformational analysis of the ligands bound to the active site of wild-type bCD38 and E218Q mutant.
NMN
+ moiety AMP moiety
Complex xN
a (6) cN
b (6) k
c (6) xA
a (6) cA
b (6) bA
d (6)
E218Q-rFNAD (Michaelis complex) +145 (anti) +161 2176 (trans) 2106 (anti) +54 2168
wt-rFNAD (covalent complex) NA +150 NA NA NA NA
+162 282 267 +155
wt-aFNAD (covalent complex) NA +158 NA 284 275 +175
+175 293 (Be)
e +34 +175
273 (Bf)
e 245 +127
aTorsion angle O49-C19-N1N(or N9A)-C2N(or C4A), defined according to IUPAC-IUB nomenclature.
bTorsion angle O59-C59-C49-C39.
cTorsion angle C2N-C3N-C7N-O7N. The conformation of the carboxamide group is defined as O7N relative to position C2N of the nicotinamide.
dTorsion angle PA-O59-C59-C49.
eBe and Bf refer, respectively, to the ‘extended’ and ‘folded’ conformations of the covalently linked ligand observed in chain B (see Figure 6).
doi:10.1371/journal.pone.0034918.t003
Structural Enzymology of Bovine CD38
PLoS ONE | www.plosone.org 11 April 2012 | Volume 7 | Issue 4 | e34918Effects of the mutagenesis of active site residues on
substrate binding
The structure of the Michaelis complex of bCD38 with rFNAD
allows establishing the potential contribution of active site residues
to the binding of the substrate. Because the conserved acidic
residues Glu138, Asp147 and Glu218 and the hydrophobic
residues Trp118 and Trp188 are predominantly involved in the
molecular reaction mechanism of the enzyme, their role will be
discussed separately (I. Kuhn et al., to be published). Here we will
mainly focus on residues Lys120, Trp168 and Arg216 which were
found to interact with the AMP moiety of the pseudo-substrate. An
alanine scanning mutagenesis was performed and the results are
given in Table 2. Surprisingly, none of these residues was found to
contribute to the overall binding energy of NAD
+. Thus the Km
values are not appreciably affected by the mutation of these
residues. Similarly the maximal rates and the percent of NAD
+
conversion into cADPR did not vary much. Altogether, these
results seem to exclude that the interactions found in the crystal
between the upper region of the active site pocket and the 59-AMP
moiety of the substrate are individually energetic enough to play a
major role in NAD
+ binding. In fact these data are rather in good
agreement with our observations concerning the conformational
flexibility of the adenosine moiety of the ligands in the crystals (see
below) and also with the poor discrimination shown by bovine
CD38/NAD
+glycohydrolase for NAD
+ analogs modified in the
adenine/adenosine moiety such as NADP
+, 1,N
6-etheno NAD
+
[63] and NGD
+ [12]. Likewise we have shown previously that
although AMP, ADP, ATP and ADP-ribose competitively inhibit
this enzyme, the observed inhibition constants were all in the mM
range [25,51]. Altogether these results indicate that the active site
of bCD38 is primarily a NMN
+ binding motif, i.e. the interactions
of the active site residues with this positively charged moiety of the
substrate are more favorable than those with the AMP moiety,
which is largely solvent exposed and conformationally dynamic
and which according to our mutagenesis studies makes, surpris-
ingly, only a minor contribution to the overall interaction energy.
Thus, in contrast with the NMN
+ moiety that interacts with a rigid
area of the bottom of the active site, the conformation of the AMP
part of the ligand observed in the Michaelis complex merely
reflects an energy minimum in the crystal rather than energetic
interactions with the protein. Moreover, residue Lys120 whose
side chain is minimally constrained and solvent exposed can only
establish low energy interactions with the pyrophosphate linkage
of the ligand.
Structure of the covalent intermediates obtained by
reaction of wild-type bCD38 with rFNAD and aFNAD
The possibility to covalently trap a reaction intermediate by
reaction of wt bCD38 with rFNAD and aFNAD ascertains the
major role played by the strictly conserved residue Glu218 in the
catalytic mechanism of this enzyme. This result also establishes the
catalytic competence of the crystallized form of wt bCD38 and the
absence of major conformational changes or domain movements
during catalysis which might have severely damaged the crystals. It
also proves that crystallized wt bCD38 is sufficiently active to
cleave the scissile bond of a slow substrate such as rFNAD, which
is turned-over by this enzyme about 4.5610
5-fold slower than
NAD
+ [37].
Fluorinated glycoside analogs have been widely used as
alternative slow substrates and mechanism-based inhibitors
providing insights into the structure and molecular mechanism
of retaining a- and b-glycosidases, i.e. enzymes known to proceed
via a covalent acylal intermediate mechanism [64]. Glycosides
substituted at position 2 by a fluorine atom present two major
properties: (i) in the absence of a C2-OH group no specific and
strong hydrogen bonding can be established with the carboxylate
moiety of the enzyme nucleophilic group; the resulting lack of C2-
OH polarization which contributes substantially to the stabiliza-
tion of the oxocarbenium ion-like transition state is much
detrimental to the catalytic efficiency of glycosidases [65]; (ii) the
presence of the strongly electron-withdrawing fluorine atom
adjacent to the reaction center also destabilizes the positively
charged oxocarbenium ion transition state by inductive effect. The
combination of both effects results in an important decrease of the
catalytic rate. One major application of the fluorinated glycosides
consists in the trapping, with inversion of configuration, of the
covalent reaction intermediate which allows the identification of
the nucleophilic carboxylic group, for example by mass spectrom-
etry and X-ray crystallography [64]. Importantly, to be successful
this strategy implies that the covalent intermediate is relatively
stable and accumulates after the first step (glycosylation) of the
catalytic process, i.e. that the deglycosylation step, which leads to
the reactivation of the enzyme, is rate-limiting. This proved to be
the case for a range of b-glycosidases with substrates having good
leaving groups, while remaining more problematic with a-
glycosidases because of the relatively fast deglycosylation process
[66]. In agreement with observations on hCD38 [67,68],
incubation of crystals of wt bCD38 with rFNAD and aFNAD
resulted in stable covalent intermediates whose structures could be
resolved at high resolution. This indicates that with rFNAD and
aFNAD we were able to manipulate the kinetic parameters of the
multistep pathway (Figure 1) and that, in sharp contrast with
NAD
+, the cleavage of their C19-N1N bonds results in the
formation of a covalent intermediate that accumulates because the
ensuing deglycosylation step is comparatively much slower,
becoming the rate-limiting step of the catalytic process. Impor-
tantly, these covalent complexes represent the first image of a
reaction intermediate poised for the second step of the catalytic
mechanism (solvolysis, cyclization, transglycosidation) (Figure 1)
and offer a complete picture of the interactions occurring with the
residues of the active site.
In both complexes, residue Glu218 was found covalently linked
to the anomeric carbon C19 of the fluorinated-ribose ring in an
axial (a-anomeric) configuration (Figure 4B). This is consistent
with a nucleophilic attack of the C19 atom of the scissile bond of
rFNAD and aFNAD by the carboxylate group of the catalytic
residue, that occurs with inversion of configuration. The released
nicotinamide, as an intermediate product of the reaction, could
not be observed in the active site, probably because of its low
binding affinity (i.e. mM range [25]) and diffusion away from the
catalytic site. In the covalent intermediate, the 39-OH group is
stabilized in both 29-fluororibose and 29-fluoroarabinose (chain A)
rings through a network of hydrogen bonds with the side chain
Oe1 oxygen atom of residue Glu218 (Glu218 Oe1
…39O d=2.7–
2.8 A ˚) and the carbonyl and amide backbone groups from residue
Trp118 (Figure 4B). Similar interactions were found between this
group and Gln218 in the non-covalent rFNAD/E218Q complex
(see above). Subtle differences exist, however, within the covalent
complexes obtained with aFNAD. Thus, in contrast to chain A
(see above), in the chain B of the dimer, the hydrogen bond
between the 39-OH group of the 29-deoxy-29-fluoroarabinoside
moiety and Oe1 oxygen atom of Glu218 is no longer observed.
Furthermore the carboxylate of Glu218 shifts away from the
center of the pocket indicating that the conformation of the side
chain of the catalytic residue and that of the 29fluoroarabinoside
are particularly affected in the covalent complex with aFNAD.
Structural Enzymology of Bovine CD38
PLoS ONE | www.plosone.org 12 April 2012 | Volume 7 | Issue 4 | e34918Importantly we ascertained that both covalent intermediates
were catalytically competent. Although they react extremely slowly
with water to produce the hydrolysis products ADP-29-deoxy-29-
fluororibose and ADP-29-deoxy-29-fluoroarabinose, their turnover
rate (i.e. reactivation of the enzyme) is significantly accelerated by
a suitable alternative acceptor such as methanol which yields the
corresponding methanolysis products (C. Cakir-Kiefer, unpub-
lished).
As in the Michaelis complex, the 29-fluorine atom of rFNAD
interacts with a conserved structural water molecule that is
hydrogen bonded by the carbonyl and amide nitrogen backbone
groups from residues Val116 and Leu137 respectively. In sharp
contrast, the 29F in the aFNAD covalent intermediate is not
involved in any bonding. It is too far away from any potential
donor or acceptor protein side chain or solvent molecule. The
torsion angle cN determined in the Michaelis complex (+ap
conformation), was preserved, for both complexes, in the
covalently linked 29F ribosyl rings. Thus, in both cases their O59
atom remains maintained in a close vicinity with the ring
O49atom.
Conformational freedom of the AMP moiety of the
covalently linked ligands
All crystal structures obtained in this work belong to the
orthorhombic space group P212121 with two molecules in the
asymmetric unit (Table 1). Both structures of the covalent
complexes revealed differences between chains A or B within the
non-crystallographic homodimers. It is not surprising to observe
different occupancies or conformations for a same ligand in the
active sites of the two distinct enzyme molecules present in the
asymmetric unit. Such subtle variations can be explained by
different crystalline lattice constraints.
The covalent complex with rFNAD. Observation of the two
distinct active sites in the dimeric structure of ADP-29-deoxy-29-
fluororibosylated wt bCD38, reveals an important conformational
flexibility of the covalently trapped intermediate. Thus, although
both copies of the enzyme contains a covalent adduct formed by
reaction between the carboxylate of Glu218 and the C19 of the N-
ribose of rFNAD, the conformation of the covalently bound
intermediates are quite different. In one copy of the enzyme (chain
B), we were able to model the complete ADP-29-deoxy-29-
fluororibosyl moiety in a folded conformation with the adenine
ring stacked at full occupancy against Trp181. Although the 2Fo-
Fc electron density map is clear in this region, some residual
density persists in the Fo-Fc electron density map contoured at
2.5s; this underlines the conformational flexibility in this region of
the intermediate. Attempts to refine alternate conformations did
not succeed (this is partially caused by a completeness of this
specific data set).
In the second copy of the enzyme (chain A), we were only able
to model the 29-deoxy-29-fluororibose-diphosphate moiety of the
covalently bound adduct. Yet the conformation of the interme-
diate is quite different since we do not see any clear density
corresponding to an adenine ring stacked against either residues
Trp168 (cf. the conformation in the Michaelis complex) or Trp181
(‘folded conformation’, see below). Both 2Fo-Fc and Fo-Fc maps
show residual density (in particular in the nicotinamide binding
region) again suggesting the existence of several conformations;
however maps are not clear enough to allow unambiguous tracing
of the ligands, probably because of rapid interconversion. We
therefore did not attempt to refine alternate conformations with
different occupancies. Due to the low affinity of nicotinamide
towards bCD38 it is unlikely that we could see traces of
nicotinamide still trapped in the catalytic pocket; we rather think
that we observe an average of conformations that are intermediate
between the folded (as seen in the other enzyme copy of the
asymmetric unit) and the comparatively more extended confor-
mation revealed by the Michaelis complex.
When the complete ligand could be observed it was found to
adopt a ‘folded’ conformation (Figure 4B). In contrast to the more
extended conformation observed in the Michaelis complex with
rFNAD where the adenine ring stacked against Trp168 (see
above), through rotations around its C49–C59 and C59–O59 bonds
the adenosine moiety has flipped over (Figure 5) and the adenine
ring is now stacked against residue Trp181, a position close to that
previously occupied by the nicotinamide ring in the active site in
the non-covalent Michaelis complex (Figure 4A). During this
process the orientation around the C49–C59 bond (torsion angle
cA; Table 3) has changed in both covalent complexes, from +sc to
2sc, corresponding to a rotation of the O59 and its attached
phosphate from above the ribose ring to a distal position (Table 3
and Figure 5E). Similarly bA made a rotation around the C59–O59
bond to adopt in both covalent complexes an +ap conformation
(Table 3 and Figure 5G). In the rFNAD/bCD38 covalent complex
the ribose ring of the AMP moiety does not interact with residues
of the active site; as in the Michaelis complex, it remains in contact
with the solvent and a water molecule (Wat234) interacts with its
29- and 39-OH groups. Moreover, its 59-phosphate remains within
bonding distance of the Lys120 side chain. At this point it is of
interest to understand the mechanics involved in the movement of
the adenine ring. Within the rigid and packed catalytic site, the
side chain of Trp181 has no conformational freedom as it is kept in
place by water-mediated hydrogen bonds involving the backbone
oxygens of Ala 146 and Leu149 and the nitrogen of the indole ring
of Trp181. These anchoring interactions are observed in all
structures: apo, Michaelis complex and covalent complexes
regardless of the ligand (rFNAD or aFNAD). Thus, the indole
ring of the Trp181 residue is kept in place to act as a rigid platform
interacting either with the nicotinamide ring during the scissile
bond cleavage step or with the adenine ring in the folded covalent
complex. On the other hand, at the solvent exposed entry of the
catalytic site, the side chain of Trp168 is fully free to rotate and
explore the entire conformational space. This conformational
freedom is observed in the crystal structures of the Michaelis and
covalent complexes with rFNAD as the side chain of Trp168
adopts two distinct and well-defined conformations. This flipping
consists in a 180u rotation around the Ca-Cb bond that literally
accompanies the movement of the adenine from the extended
conformation (stacked against Trp168) to the folded conformation
(stacked against the rigid Trp181). Furthermore, the substrate
being tightly kept in place around its two phosphates, flipping the
adenine can thus only be achieved, as observed (Figure 5), through
a rotation around the C49–C59 and C59–O59 bonds of the
adenosine moiety. Finally, because Trp168 also blocks the upper
part of the active site, such rotation has to be unidirectional.
The covalent complex with aFNAD. Comparison of the
covalent complexes obtained with rFNAD and aFNAD allows
observing subtle differences that distinguish the way the active site
of bCD38 accommodates both ligands. With aFNAD, while one
active site (chain A) clearly favors a unique conformation similar to
the one observed for rFNAD, the second site reveals the presence
of two conformations of the covalently trapped intermediate. It is
possible that the fluoride atom in aFNAD slows down the ‘adenine
flipping’ described above based on the comparison between the
Michaelis complex and the covalent-intermediate obtained with
rFNAD. This allowed us to capture a snapshot of this fast
equilibrium using X-ray crystallography, i.e. to observe the
coexistence of both conformers in the same catalytic site. This is
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able to observe two extreme conformations probably representing
two distinct states along the ‘catalytic trajectory’ followed by
CD38. The recent structures of hCD38 revealed six slightly
different conformers of the same covalent adduct [69] where the
substrate already adopts the folded conformation ready for
cyclization, which is not the case in our study.
Electron density maps (2mFo-DFc and Fo-DFc) indicate the
presence of two conformations. Attempts to refine simultaneously
the two alternate plausible conformations suggest a 1:1 equilibri-
um of populations; however, those numbers should be taken with
caution, as maps remain noisy even after occupancy refinement of
the two alternate conformations (Figure 6). For the indole ring of
Trp168, the rather poor electron density map quality clearly
indicates a greater conformational freedom for this side chain, as it
oscillates between a ‘locked’ conformation (i.e. stacked against the
adenine of the ligand as seen in the Michaelis complex) or a more
‘relaxed’ conformation (where the adenine has flipped to stack
against Trp181 as seen in the rFNAD covalent complex); this
probably results in an averaging and smearing of the electron
density in the corresponding area (Movie S1).
Conformational freedom of the AMP moiety and ADP-
ribosyl cyclase activity
In all these covalent structures the adenosine ring retains the
original thermodynamically favorable anti-conformation (see xA
values in Table 3). Consequently, the distance between its N1
position and the anomeric carbon C19 (about 9.5 A ˚ in the covalent
complex with rFNAD) remains too large to make a cADPR
derivative. Thus this covalent complex, in which the adenine ring
is stacked against Trp181 in an anti conformation, is a non-
productive one with regard to the ADP-ribosyl cyclase activity of
bCD38 (Figure 1). In contrast, a rotation around the N9-C19 bond
of the adenosine moiety, which can take place without collision
with the protein, would result in an energetically unfavorable syn
conformation (xA changes from 282u to an estimated +77u) and
bring the N1 nitrogen at about 3.2 A ˚ of the covalenty bond N-
ribosyl C19. This distance is much more favorable to the
cyclization since the positioning of the anomeric carbon of the
ribooxocarbenium ion reaction intermediate (Figure 7) is expected
to be even closer by 1.5 A ˚, i.e. at a binding distance of N1 (see
below the discussion on the ‘electrophilic migration’ process).
However, because the proportion of cADPR formed by CD38 is
very low (,2% reaction products), the syn conformation is most
probably a very minor one and this low population could explain
why it is not seen in the crystals. Interestingly, the high yield of
cyclization of the surrogate substrate NGD
+ [70] into cyclic GDP-
ribose catalyzed by bCD38 [12] might imply that in the
intermediary complex, the guanine ring is also stacked against
Trp181 in its energetically favorable anti conformation. In that
case however, the anti conformation is highly favorable because the
cyclization process involves the more nucleophilic N7 position of
the purine ring [70].
In the covalent complex with rFNAD the adenine ring which is
now face-to-face p- stacked against Trp181, is also stabilized
within the active site by polar interactions with the side chains of
Glu138 and Asp147 which, in the Michaelis complex, were
originally hydrogen bonded the nicotinamide amide nitrogen of
the substrate (Figure 4B). Thus, the exocyclic N6 amino group
gives hydrogen bonds with the Oe1 of Glu138 (d=2.6 A ˚) and the
Od1 of Asp147 (d=2.8 A ˚). As mentioned previously, the Oe2o f
Glu138 remains hydrogen-bonded to the Ne1 of the imidazole
ring of the conserved residue His126. In addition, the N1 atom of
the adenine is also hydrogen bonded to the backbone amine of
Gly148. Importantly, and in sharp contrast with the Michaelis
complex, the entrance of a water molecule within this non-polar
environment accompanies the departure of nicotinamide from the
active site at the issue of the first step of the reaction process. This
molecule (Wat131 in the rFNAD/bCD38 complex) which is
ideally poised to play the role of the nucleophilic acceptor in the
last – and macroscopically irreversible – step of the catalytic cycle
(Figures 1 and 7), is maintained on the top-face of the ribose at
about 3.9 A ˚ from the anomeric carbon C19 by short hydrogen
bonds (d=2.6 A ˚) with the Oe1 of Glu138 and the N7 of the
adenine ring. This contrasts with the adenosine in its syn
conformation, which establishes less interactions with the active
site (N6 hydrogen bonded to the side chain of Glu138) and which
fills the space occupied by the putative nucleophilic water
molecule. Altogether, it is likely that these interactions also
contribute to the stabilization of the anti conformation of the
adenosine moiety within the active site and consequently may
impede the ADP-ribosyl cyclase activity of bCD38. Although
CD38 is the only characterized mammalian enzyme able to
transform NAD
+ into the calcium-mobilizing metabolite, cADPR,
our structural data strongly suggest that its active site has not been
optimized to carry out such a cyclization reaction.
The conformational flexibility of the AMP moiety in the
covalent complex uncovered by our structural studies most
probably implies that, like the interaction/desorption of the
leaving group nicotinamide, the stacking of the adenine ring
against Trp181 exists in a rapid on and off equilibrium in this
reaction intermediate. This unstacking is required for the
adenosine moiety to adopt a syn conformation favorable to the
cyclization reaction and also for acceptor pyridines to access the
anomeric carbon from the top-face of the ribooxocarbenium ion
intermediate in order to engage in base-exchange reactions with
retention of configuration. It should be noted however that the
absence of interactions between residues of the active site of
bCD38 with the A-ribose moiety does not allow the enzyme to
enforce, via pseudo-rotation, a C29-endo conformation of the ribose
which is more favorable to the syn conformation of the adenine
ring i.e. favorable to cyclization. This might also contribute to the
low yield of cADPR.
From a mechanistic perspective, it seems that the active site of
CD38 has evolved to initially recognize and bind the NMN
+
moiety of the NAD
+ substrate and, in the first step of the catalytic
pathway, to catalyze the cleavage of the nicotinamide-ribosyl
bond; the motion of the adenosine moiety ring occurs subse-
quently in a second step. The movement and the stacking of the
adenine ring against Trp181 could help to expel nicotinamide
from the catalytic site, thus completing the first step of the reaction
process and making it nearly irreversible. The conformational
change of the ADP-ribosyl intermediate (isomerization step) after
cleavage of the scissile bond might also be part of the rate limiting
step in the CD38/NAD
+glycohydrolase catalyzed hydrolysis of
NAD
+. This could explain the results obtained: i) by the group of
E. Cordes which has shown that in NAD
+glycohydrolase-
catalyzed hydrolytic cleavage of NMN
+ and NAD
+,a na-
secondary
2H kinetic isotope effect was only observed with the
mononucleotide substrate [71], and ii) in the studies on intrinsic
fluorescence quenching of native CD38 by (pseudo)substrates [72].
In conclusion, the cyclase activity of bCD38, which involves a
rearrangement of the ligand within the catalytic site, represents a
remarkable case of steric exclusion between the substrate NAD
+
and nicotinamide, one of the reaction products, that has to diffuse
out of the binding pocket to allow the reaction to proceed.
Moreover, within the active site, the adenosine moiety of the
substrate must be flexible enough to be able to adopt both anti (the
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ribosyl cyclase activity of bCD38) and syn conformations. Only an
adenosine moiety adopting the energetically unfavorable syn
conformation would allow the adenine ring stacked against
Trp181, to be positioned into a ‘near-attack conformation’ [73]
resulting in the formation of cADPR. However, our structural
studies show that the anti conformation, which is favored
thermodynamically [59,74], is also stabilized by specific interac-
tions with the active site of bCD38. It thus seems that the design of
the active site of CD38 is not optimized to make cADPR and that
formation of this important metabolite rather results from a
stochastic conformational choreography.
Conclusion
This study represents a comprehensive structural and mecha-
nistic analysis of bovine CD38/NAD
+glycohydrolase which was
successfully crystallized in its N-glycosylated form. Compared to
the other members of this enzyme family, bCD38 is a shorter
polypeptide and lacks an otherwise highly conserved disulfide
bond. Despite these differences, the overall three dimensional
structure of bCD38 is identical to that of Aplysia californica ADP-
ribosyl cyclase (1.9 A ˚ Ca rmsd for 30% sequence identity) [23]
and hCD38 (1.2 A ˚ Ca rmsd for 48% sequence identity) [21]. In
analogy with this latter enzyme, the back-to-back homodimeric
bCD38 observed within the asymmetric crystallographic unit also
contains a disulfide bond seemingly specific to the mammalian
CD38 and stabilizing their hinge region. The active site of bCD38
consists in a funnel-shaped cavity with a fairly rigid structure; it
buries the NMN
+ moiety of the substrate and its scissile bond in its
deepest non-polar and least solvent accessible region, whereas the
AMP moiety interacts with its more solvent-exposed region, at the
entrance of the catalytic cleft. Comparison of the structures of apo
Figure 6. The conformational flexibility of the substrate revealed in the covalent complex between wt bCD38 and aFNAD. (A) Stereo
view showing the ‘extended’ and ‘folded’ conformations simultaneously observed for the 29-fluorinated arabinoside covalently bound to the catalytic
residue Glu218. Two alternate conformations of the covalent intermediate with aFNAD were trapped within the same catalytic site of wt bCD38
(monomer B). The figure highlights the change of stacking interactions established by the adenine ring after its rearrangement from the more
extended conformation (stacked against Trp168) as observed in the Michaelis complex with rFNAD (Figure 4A) to a constrained conformation
(stacked against Trp181) as observed in the covalent complex with rFNAD (Figure 4B). Hydrogen bonds are indicated with black dashed lines. (B)
Superimposition of the three alternate conformations adopted by aFNAD, one in monomer A (green – stacked against Trp181) and two in monomer
B (blue), highlighting the alternate conformations adopted by conserved residues Trp168 and Glu218 (bold labels). Within the two active sites present
in the crystallographic asymmetric unit, the two observed ‘extended’ aFNAD conformations are virtually identical. Residues critical to substrate
binding and catalysis are labeled. Both views are shown under the same relative orientation.
doi:10.1371/journal.pone.0034918.g006
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complexes obtained in presence the 29-fluorinated analogs of
NAD
+, rFNAD and aFNAD, provides invaluable insights into the
multistep pathway of this enzyme allowing for the dissection of its
catalytic mechanism. In the Michaelis complex the binding energy
is seemingly used to enforce an unusual and constrained
conformation of the NMN
+ moiety as manifested by (i) the spatial
vicinity of the 59-oxygen with the ribose ring O49, and (ii) an
orientation of the nicotinamide ring that corresponds to a high
energy conformation. This ground-state destabilization, in addi-
tion to the hydrophobic environment and the desolvation of the
nicotinamide-ribosyl bond, promotes the lengthening and cleavage
of the scissile bond via a dissociative transition state and the
formation of a ribooxocarbenium ion reaction intermediate
(Figure 1). This intermediate is electrostatically stabilized by the
side chain of Glu218, the catalytic residue, which also plays a
paramount importance in catalysis by polarizing the 29-OH of the
substrate NAD
+. The structures of the covalent intermediates
obtained by reaction of wt bCD38 with the slow substrates rFNAD
and aFNAD, underline the dynamics of the AMP moiety of the
substrates characterized by the movement of the adenine ring
which stacks alternatively with Trp168 and Trp181. In all
conformations found the adenine ring remains in the thermody-
namically most stable anti conformation, which is not spatially
favorable for the formation of cADPR. The low proportion of the
cyclic metabolite formed by this enzyme seems linked to the anti-
syn equilibrium of the adenosine moiety in the reaction
intermediate. It thus appears that the active site of CD38 has
not evolved to optimize its ADP-ribosyl cyclase activity relative to
the irreversible hydrolytic step leading to ADP-ribose (Figures 1
and 7). Thus, from a purely structural and mechanistic perspective
the ADP-ribosyl cyclase activity of CD38 rather seems to
correspond to a competitive and opportunistic alternative reaction
pathway resulting from a stochastic event. In line with the
‘topological paradox’ of CD38, such a conclusion might seem an
additional paradox for the biosynthesis of cADPR, an important
secondary messenger in the mobilization of cellular Ca
2+. Finally,
from a structural viewpoint, knowledge of the precise nature of the
interactions of bCD38 with its substrates obtained in this study
should facilitate structure-based design of specific and efficient
inhibitors for this class of enzymes and also provide models for
virtual screening.
Materials and Methods
Expression and purification of bovine CD38/
NAD
+glycohydrolase
The DNA fragment encoding the ecto-domain (residues 32–
278) of bCD38 [13] was cloned into the expression plasmid
pPICZaA (Invitrogen) in frame with the yeast a-factor secretion
signal sequence under the transcriptional control of the AOX1
promoter and keeping its original stop codon [20]. The
recombinant glycosylated enzyme was expressed as a secreted
protein in methanol-induced Pichia pastoris strains GS115 or X33
[20]. Mutagenesis of bCD38 was done by PCR using the
commercial QuikChange Site-Directed Mutagenesis kit (Strata-
gene). To avoid translational misincorporation during protein
synthesis, mutations were systematically obtained by a double-base
pair substitution. Soluble wt and mutant secreted bCD38 proteins
were recovered from the supernatant of the yeast cultures and
purified to homogeneity (SDS-PAGE) by affinity chromatography
on a Blue Sepharose 6 Fast Flow CL-6B column (Amersham
Biosciences) [20]. To prevent any contamination by wild-type
enzyme, each mutant was purified on a dedicated affinity column.
Protein concentrations were determined by the OD at 280 nm
and by the BCA protein assay (Pierce).
Crystallization
Bovine CD38 wt or mutant E218Q, both monoglycosylated at
position N201 [20], were dialyzed against 20 mM Hepes
(pH=7.4) and concentrated to 5–10 mg/mL for crystallization
trials. For the apo-enzyme, high-throughput crystallization screen-
ing was performed using the nanoliter robotic workstation
Mosquito (TTP LabTech) using vapor-diffusion crystallization
technique in hanging drop setups at room temperature. Thirty
initial crystallization conditions were found out of the 864
screened. Best crystals grew in 20–30% PEG 4000, 50–250 mM
ammonium sulfate and 100 mM sodium cacodylate, sodium
acetate or MES at pH=6.0–6.5 and were flash-frozen in mother
liquor supplemented with 20% ethylene glycol or glycerol.
Covalent and non-covalent complexes with aFNAD [75] or
Figure 7. Competition between the NAD
+glycohydrolase and ADP-ribosyl cyclase activities of bCD38. The formation of cyclic ADP-
ribose entails a syn conformation of the adenosine moiety in the reaction intermediate bringing the N1 of the adenine ring in the vicinity of the C19
position of the ribooxocarbenium ion. The thermodynamic equilibrium is in favour of the anti conformation.
doi:10.1371/journal.pone.0034918.g007
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temperature with 1 to 3 mM ligand followed with a short 2 min
soak with the cryo-protection solution also containing 1 to 3 mM
ligand.
X-ray data collection and structure determination and
refinement
Diffraction data were collected at the Advanced Light Source
beam line 8.3.1 at the Lawrence Berkeley National Laboratory
(Berkeley, California). All crystals of the glycosylated form of
bovine CD38 belong to orthorhombic space group P212121 with
two molecules per asymmetric unit and diffracted at resolutions
ranging from 1.55 to 1.95 A ˚ for an average solvent content of
47%. Within the asymmetric unit, the two monomers are related
by a non-crystallographic quasi two-fold axis of symmetry. Data
were reduced and scaled using HKL2000/SCALEPACK [76] or ELVES/
SCALA [77]. The initial apo wt bCD38 structure was solved at 1.8 A ˚
resolution by molecular replacement with PHASER [78] using the
hCD38 structure (PDB code 1yh3) as search probe. Following the
initial molecular replacement solution, automatic building using
ARP/WARP [79] followed by refinement using REFMAC [80] then
PHENIX [81] and manual model building in COOT [82] yielded the
final structure including residues Ser37 to Leu275 and Gly38 to
Arg277 for monomers A and B respectively, together with water
molecules. To minimize model bias, the mutant and all liganded
structures reported in this study were solved by molecular
replacement using our apo wt bCD38 structure and refined in
PHENIX. The bCD38mt in its apo form or bound to aFNAD
respectively diffracted to 1.55 A ˚ and 1.58 A ˚ resolution whereas the
form bound to rFNAD diffracted to 1.94 A ˚. The wt bCD38 bound
to aFNAD and rFNAD respectively diffracted to 1.95 A ˚ and
1.78 A ˚ resolution. For the mutant E218Q bCD38 enzyme bound
to rFNAD, observation of the initial Fourier synthesis Fo-Fc
difference map derived from molecular replacement revealed
density corresponding to the non-covalently bound ligand
(Michaelis complex). For wt bCD38 bound to aFNAD or rFNAD,
observation of the initial Fourier synthesis Fo-Fc difference map
derived from molecular replacement revealed density correspond-
ing to the ligand covalently bound to the strictly conserved residue
Glu218 in the catalytic site. In order to investigate the subtle
differences between the two catalytic sites, non-crystallographic
symmetry averaging was NOT applied during refinement. Ligands
were generated using eLBOW and were explicitly included when
refinement of the protein model showed reasonable convergence.
For wt bCD38 bound to aFNAD, two alternate conformations of
aFNAD were modeled (in chain B) and their relative occupancies
were refined in PHENIX. In all liganded structures, all sites
appear to be fully occupied. The electron density maps of the
ligands are shown in Figure S5. Alternate conformations of side-
chains were also included. In all structures the two first N-Acetyl
glucosamine units of the N-linked carbohydrate chain at residue
N201 were observed. The quality of each structure was evaluated
using MOLPROBITY [83]. The figures were generated with PyMOL
[84].
Enzyme assays and kinetic studies
The enzyme activity was measured as described previously
[14,85,86]. Steady state kinetic studies were performed accord-
ingly. Briefly, the enzyme was incubated at 37uC with NAD
+ (5–
400 mM) and 2.5610
5 dpm [adenosine-U-
14C] NAD
+ (Amersham
Biosciences) in 200 mL (final volume) 10 mM potassium phosphate
buffer at pH 7.4 (buffer A). At selected times, 50 mL aliquots were
removed and treated with ice-cold perchloric acid (2% v/v final
concentration) to stop the reaction. After neutralization with
K2CO3, the precipitated proteins were removed by centrifugation
and product formation was monitored by HPLC.
Analysis of the reaction products was performed on a 30063.9-
mm mBondapak C18 column (Waters Assoc.). The isocratically
eluted compounds (10 mM ammonium phosphate buffer at
pH 5.5 containing 0.8–1.2% (v/v) acetonitrile; flow rate: 1 mL/
min) were detected by absorbance recordings at 260 nm and by
radiodetection (Flo-one, Packard Radiometric Instruments) when
using [
14C] NAD
+. Peaks were identified by comparison with
authentic samples, and areas obtained from UV recordings were
normalized using the molar extinction coefficients of the reaction
products. When indicated cADPR was also determined using a
cycling assay [85].
Kinetic parameters Km and kcat were determined from the plots
of the initial rates of product(s) (ADP-ribose+cyclic ADP-ribose)
formation as a function of substrate concentration (8 data points)
according to Michaelis–Menten kinetics, using a GrapPad Prism
nonlinear curve fitting program (GrapPad Software). Alternatively
NAD
+glycohydrolase activity was determined by a sensitive
continuous fluorometric method using 1,N
6-etheno NAD
+ (e-
NAD
+, Sigma) as substrate, as previously described [4]. This assay
was performed in a thermostatically controlled fluorimeter cuvette
at 37uC in 1 mL (final volume) of buffer A. It consists of measuring
an increase of fluorescence (Shimadzu, RF 5301 PC) at
lem=410 nm (lexc=310 nm) resulting from the hydrolytic
conversion of the dinucleotide to 1,N
6-etheno ADP-ribose.
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